LATITUDE Ulcerative Colitis Studies

Let's

navigate

Ulcerative Colitis

together

Let's

navigate

Ulcerative Colitis

together

Let's Navigate Ulcerative Colitis Together

If life with ulcerative colitis feels like it revolves around constant planning, pain, and uncertainty, explore a different route with the LATITUDE UC Study.

Did You Know?

UC most commonly develops in people 15–30 years old, but it can develop in people of any age.1 That’s why researchers continue to seek effective treatment options for people of all ages.
UC symptoms can be mild, but more than 1 in 5 people have a moderate to severe case.2 Researchers are looking for ways to help them.
Having UC can be stressful, and those with higher perceived stress levels have a greater chance of experiencing a flare.3
Flares can impact so much of daily life—outings with friends, what to eat, when to leave the house, and much more. Evidence suggests that 87% of people with UC have an impaired quality of life.2
Over time, UC has become more common around the world,4 and in some locations, there has been an increase in the prevalence of UC in communities of color.5 That’s why it’s important for people from all communities to be represented in clinical research.

Explore a different route for potential relief with the LATITUDE UC Study.

You may be able to participate in the LATITUDE UC Study if you:

Are 18–75 years old
Were diagnosed with ulcerative colitis (UC) and are currently experiencing symptoms
Have tried at least 1 other treatment for your UC that didn't work
Are interested in an investigational oral treatment

If you are interested in participating, the study doctor or staff will review additional study criteria with you.

Qualified participants will receive all study-related medications and study-related care at no cost. Participants may be compensated for travel and expenses.

About the LATITUDE UC Study

The LATITUDE UC Study is evaluating the efficacy and safety of an investigational oral treatment for ulcerative colitis (UC). Participants will receive the investigational treatment or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.  

Participants originally assigned to placebo will have the opportunity to switch to the investigational treatment after the 12-week induction period. All study treatments will be given as oral pills.   

Neither participants nor the study staff will know if participants are receiving the investigational treatment or a placebo. Participants will attend up to 14 scheduled study visits (and any additional study visits if needed) over the course of about a year.  

© 2023–2024 Clinical Trial Media. All Rights Reserved.